FOXP3 and melanoma: Moreover, the MFI of PD-1 on CD4+, CD4+FOXP3+, CD8+T-cells (mean ± SD: 603.03 ± 805.10 vs. 459.13 ± 721.08, p=0.35; 1216.89 ± 1573.47 vs. 1084.14 ± 1829.87, p=0.7 and 605.69 ± 1023.86 vs. 923.40 ± 2109.77, p=0.37, respectively) have shown no significant differences between stage III and stage IV melanoma patients.